Mr Fang Qi > Fangda Partners > Beijing, China > Lawyer Profile

Fangda Partners offers an extensive life sciences and healthcare focussed team representing an array of medical technology companies and investors, both PRC and multinational. The team is particularly recommended for its expertise in financing and fundraisings. Practice head Josh Shin is expert on regulatory-related issues including R&D, clinical trials, HGRAC regulation and patient centric transformation. Kate Yin is recommended for handling investigations work in the healthcare space, covering anti-bribery, accounting fraud, securities law, conflict of interest, trade secrets and data security. IP expert Fang Qi, antitrust investigations specialist Michael Han and the M&A and foreign investment focussed Diana Li are also central to the team. Henry He, who joined the firm from C-Stone Pharmaceuticals in January 2023, is a further key name.

One of the few firms in China with an established IP appellate litigation and advocacy practice, Fangda Partners‘ enviable track record includes numerous appearances before both the country’s provincial high courts and PRC Supreme Court. On the non-contentious side, the practice covers domestic and cross-border deals involving procurements, acquisitions, assignments, licensing, brands, patents and copyright. The team is co-led by renowned IP litigator Alexandra Yang and former Shanghai High People’s Court judge, James Hu. The department further includes IP infringement and anti-counterfeiting specialist Richard Lin; Fang Qi, an adviser to pharmaceutical, biotechnology, petrochemical, telecoms, and manufacturing companies; and Hans She, whose experience covers high profile non-contentious proceedings. Also key to the group, Claudia Yun assists with IP-related transactional and litigation work, while Tingting Liao predominantly focuses on patent litigation and invalidation matters, as well as trade secret disputes. The counsels to note are Christine Dong and Lin Qin.